Notably, Tsubasa Miyazaki and colleagues investigated the effects of combining anti-PD-L1 antibodies with an M2 macrophage inhibitor called Eganelisib (referred to as IPI-549) on tumor growth. Here, CD274 is linked to neoplasm.